U.S. court revives lawsuit over Bristol Myers' delayed cancer drug
Plaintiffs allege delayed commercialization of Bristol Myers Squibb's cancer treatment led to financial harm. Case sent back for further review.
A U.S. appeals court on Friday revived a lawsuit accusing Bristol Myers Squibb of delaying the commercialization of a cancer drug, allowing plaintiffs to pursue claims of financial harm.
The U.S. Court of Appeals for the Second Circuit overturned a lower court's dismissal of the case, ruling that the plaintiffs had plausibly alleged that the delay caused them economic losses. The decision remands the matter for further proceedings.
The lawsuit centers on Bristol Myers' handling of a cancer treatment, with plaintiffs contending that the company's actions resulted in delayed market availability and corresponding financial damages. Specific details of the drug or the plaintiffs' claims were not disclosed in the court filing.
Bristol Myers Squibb, a major pharmaceutical company, has not publicly commented on the revived lawsuit. The company's shares were not materially affected by the ruling, according to market data.
Legal analysts noted that the case highlights the potential financial and reputational risks pharmaceutical firms face when managing drug development timelines and commercialization strategies.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →